STAT+: Pharmalittle: Sarepta Duchenne therapy misses primary endpoint; FDA holds panel for first CRISPR treatment for sickle cell
Sarepta said its gene therapy for Duchenne muscular dystrophy failed to improve muscle function compared to a placebo in a large clinical trial.
Rise and shine, everyone, another busy day is on the way. We can tell by the early hour the official mascots bounded outdoors to chase their breakfast and the increasing volume of or . Meanwhile, we have gathered another menu of tidbits for you to peruse as you attempt to manage the moment. On that note, we hope you conquer the world today. Best of luck, and do keep in touch. …
